Randomized Trialhigh evidence

Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

Nature medicine·April 2, 2026·PMID 41928037

Why it matters

Patients with obesity and cardiovascular disease often have concurrent liver fibrosis, which amplifies cardiovascular risk. This analysis confirms that semaglutide’s cardiovascular protection is preserved in this high-risk subgroup and may offer additional hepatic benefits, supporting its use in patients with overlapping cardiometabolic and liver concerns.

Infographic summary of Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Visual abstract · MedLit

The papers that matter, first.

MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.

§

MedLit · Evidence, Distilled